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ABSTRACT   
Background: Breast cancer is the leading cancer in Sudanese females.  
Objectives: This study was done to evaluate the clinical response to neoadjuvant chemotherapy for 
patients treated at National Cancer Institute (NCI) and to compare it with the published literature.  
Methods:  This is a retrospective study conducted in National Cancer Institute (NCI), Gezira State, 
Sudan during the period from April 2005 to August 2011. We studied the data for all patients who 
have locally advanced breast cancer and treated at NCI during study period. Patients who remained 
inoperable after treatment were considered as having no response to therapy. Data were introduced 
and analyzed using SPSS software. Data evaluated includes Patient age, disease stage, 
chemotherapy regimens, and number of cycles, tumor histology, grade and histopathology after 
chemotherapy.  
 Results: A total of 110 patients who received neoadjuvant chemotherapy and fulfilled criteria for 
inclusion during the period 2005 to 2011 were evaluated.   
Majority of patients were between 30-50 years of age (63%). Patients who achieved response and 
had surgery were 65%. Among those who underwent surgery 22% have complete pathological 
response. Most of patients who achieved complete histopathological response had six cycles of 
chemotherapy.  
Conclusion: this study demonstrated that neoadjuvant systemic therapy is an accepted approach for 
women with locally advanced breast cancer for whom immediate surgery is inappropriate, and we 
achieved results similar to the international literature.   
Key words: breast cancer, neoadjuvant, chemotherapy, response, NCI, Sudan. 
  
reast cancer is the most frequently 
diagnosed cancer and a second 
leading cause of cancer death after 
lung cancer among females worldwide1.  
A number of studies have suggested that there 
are epidemiological differences between 
breast cancers among women in Europe and 
Africa. Risk factors such as menopause, oral 
contraceptive use, cigarette smoking, and 
family history of breast cancer have been 
shown to have different relations to breast 
cancer among blacks and whites2. 
Breast cancer in African women is 
characterized by younger age at onset, 
advanced stage at diagnosis, and consequently 
_________________________________________________ 
1. Oncology Department, National Cancer Institute, 
University of Gezira, Sudan  
2. Clinical Oncologist, Radiation and Isotope Center – 
Khartoum, Sudan   
*Correspondent: dafaallahi@yahoo.com  
poor prognosis3-5. In Africa, mastectomy 
rate is more than 85%, compared to just 30% 
in Europe6.   
Neoadjuvant systemic therapy is the accepted 
approach for women with locally advanced 
breast cancer for whom immediate surgery is 
inappropriate and is an option for women with 
operable breast cancer, particularly when, 
based on tumor size, mastectomy rather than 
conservative surgery is indicated, and the 
patient desires an attempt at breast 
conservation7-10. Neoadjuvant chemotherapy 
was developed in the 1970s with the aim of 
improving outcomes in patients with locally 
advanced breast cancer11-12. With the 
development of more effective chemotherapy 
regimens, including taxane combinations, 
neoadjuvant chemotherapy now achieves a 
clinical response rate of 60 to 90 percent and 
pathologic complete response rates ranging 
from 10 to 30 percent13- 14.   
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Since breast cancer is the most frequent 
cancer among women in Sudan and patients 
tend to come at late stage. There is an urgent 
need to assess response of neoadjuvant 
chemotherapy and if there is prognostic factor 
for that response. In this study we are to 
provide some answers.  
Material and methods:  
This retrospective study is conducted at NCI, 
University of Gezira, Wadmedani, Sudan. 
NCI was established in 1999 as the second 
cancer center in Sudan to serve the heavy 
populated States in central Sudan. Most 
modalities of anticancer treatment are 
available. Chemotherapy, radiotherapy and 
hormonal therapy are provided at NCI, while 
surgery is done in Wadmedani teaching 
hospital. Targeted therapy is not available in 
Sudan most probably due to its terribly 
expensive cost. All breast cancer cases 
attended NCI for treatment, are seen at the 
combined breast cancer clinic which was 
established in 2000. Gezira protocol for breast 
cancer was adopted in 2004, updated in 2006 
and finally, a national breast cancer treatment 
guideline was adopted in 2010.    
According to this protocol; cases with locally 
advanced tumor (stage IIB and III) will 
receive neoadjuvant systemic chemotherapy. 
Patients with stage IIA who present with big 
tumor relative to breast size and wish to have 
conservative surgery will also receive 
neoadjuvant treatment. According to 
guidelines the first line chemotherapy 
constitutes of Adriamycin, 
Cyclophosphamide and 5 Fluorouracil (CAF), 
patient with potential cardiac problems has 
methotrexate to substitute Adriamycin 
(CMF). Taxane (docitaxel and paclitaxel) - 
based chemotherapy (TAC) is used as second 
line and for young ladies with high risk tumor 
characteristics (less than 35years). Patients 
who shows good clinical response (>75% 
reduction) undergo breast conservative 
surgery provided that there are no other 
indications for mastectomy. Patients who 
achieve partial response will undergo 
mastectomy. In both conditions axillary 
clearance is performed. Patients with less than 
25% reduction in tumor size will be 
considered as non-responders and will have 
surgery “whenever possible”.  
After surgery all sample will be submitted to 
histopathology and report has to include 
viability of tumor cells (or necrosis), type of 
histology, grade, lymph vascular-invasion, 
margin status, number of retrieved lymph 
nodes and number of involved nodes. 
American Joint Committee for Cancer staging 
(AJCC) and Tumor, Lymph node and 
Metastasis (TNM) is used for staging.  
In this retrospective study we searched files of 
all breast cancer patients who received 
neoadjuvant systemic chemotherapy (2005-
2011) for age, stage, type of chemotherapy 
given, number of cycles prior to surgery, 
operability, type surgery performed and 
histopathological response. Patients who 
discontinued their treatment, unable to have 
histopathology after surgery and those with 
metastatic disease were excluded. Well-
structured questionnaire filled from records. 
Data was introduced and, then analyzed by 
using statistical package for social sciences; 
(SPSS).  
Results:  
Total number of patients who are fulfilling 
criteria for evaluation   
were 110. Majority of patient ages were 
between 30-50 years (63.6%), while patient 
over 50 years of age are (27.3%) and patients 
who are 30 years or less represents 9.1% 
(table 1). The median age for the study 
population is 45 years. Almost 94.6% of 
patients were stage III and 5.4% were stage II. 
Invasive ductal carcinoma was the dominant 
histopathology and seen in 90% of cases and 
lobular carcinoma was seen in 3.6%. Most 
patients had tumor grade II (48%) or III 
(47%), while grade 1 was seen in only 5%. 
Tumor characteristic is shown in table 2. 
Number of patients treated by CAF regimen 
were 80.9%, CMF 13.6% and 3.6% received 
taxane- based chemotherapy regimen (table 
3). Some patient responded to total of three 
cycles or less of chemotherapy (25%) and 
most of them showed response after four-six 
cycles (67%) and only 8% received more than 
six cycles. Good clinical response was 
achieved in 81%. On the other hand 19% of 
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patients showed poor response and remained 
inoperable. From the responders 19% were 
able to undergo conservative surgery (table 
4). Complete pathological response was seen 
in 22.7%. No single patients from those 
received more than six cycles showed 
complete pathological response (figure 1). 
Table 1: Age distribution of studied patients. 
(Total number: 110). 
Age distribution  Percentage 
21-30  9.1  
31-40  30 
41-50  33.6  
51-60  10.9  
61-70  9.1  
71-80  6.4 
81-90  0.9 
Total  100  
Table 2: Stage and tumor characteristic prior 
to treatment of the studied patients  
Stage (%) Histopathology (%) Grade (%) 
I (0) Ductal (90) I (4.5) 
II (5.4) Lobular (3.6) II (48.2) 
III (94.6) Others (6.4) III (47.3) 
Table 3: Different chemotherapy regimen 
used by the studied patients. 
Regimen  Total (%) 
CAF/ AC  (63.6) 
CMF  (13.6) 
TAC  (3.6) 
AC  (1.8) 
First and second lines  (19.1) 
Discussion: 
Neoadjuvant chemotherapy is increasingly 
being used in the management of patients 
with large operable and locally advanced 
breast cancers. This treatment is administered 
in the hope that down-staging might lead to 
avoid mastectomy, as an in vivo measure of 
chemo-sensitivity, and to enable systemic 
treatment of occult micrometastatic disease15. 
Table 4: Type of surgery done after treatment 
of studied patients. (Total number: 110) 
Surgery  percentage 
Mastectomy  65.5 
Conservative  15.5 
Inoperable  19.1 
Total  100% 
 Figure (1): Histopathological response 
according to number of cycles. 
(Residual: viable tumor; Fibrosis: complete 
histopathological response).  
Randomized trials comparing pre-operative 
and post-operative adjuvant chemotherapy in 
early breast cancer show similar rates of local 
control and overall survival (OS), but the 
mastectomy rate is lower with the pre-
operative approach16.  
Existing studies show that the patients who 
benefit the most from neoadjuvant 
chemotherapy are those who achieve a 
pathological complete response (PCR) with 
no residual microscopic tumour. This is 
relatively uncommon, occurring in only 3–
16% of patients17,18.   
Regarding age group among the study 
population, 30 – 50 predominated 70 cases 
(66.6%), the common age in Western studies 
is found to be 50 years or above.   
This observation is consistent with the 
literature and has been reported in several 
other studies conducted in sub-Saharan 
Africa19, 20. A higher incidence of breast cancer 
in younger women has also been observed in 
women of African descent residing in western 
countries21.   
The most stage grouping found among the 
study population was IIIB (53.6%) nearly 
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equally distributed between negative and 
positive receptor status, and it seemed to be 
selected for neoadjuvant therapy, while stage 
IIIA, IIB and IIA represented only (15.5%), 
only two cases (1.8%) were found to have 
bone metastasis while on treatment. 
Regarding type of chemotherapy, most of 
patients received CAF regimen (61.8%) 
according to the adopted protocol. Patients 
receiving anthracycline-based chemotherapy 
are more likely to achieve a PCR than those 
receiving non-anthracycline regimens. 
NSABP-18 studied anthracycline and non-
anthracycline regimens in operable breast 
cancer anthracycline regimens in favour of 
12% reduction of recurrent and 11% 
reduction of deaths. Addition of taxane to 
anthracycline had resulted in high 
pathological complete response (PCR) rate 
and survival benefits, the cost and availability 
restricted taxane use previously.   
Most of patients received six cycles, followed 
by those who received three and four cycles, 
it was found that, response to chemotherapy 
increases with increasing of cycle’s number 
up to six cycles, further cycles do not affect 
the response. NSABP-B 27 showed that eight 
courses of sequential pre-operative 
chemotherapy are superior to four cycles in 
term of PCR and DFS. Probably six cycles of 
an active regimen is sufficient in Neoadjuvant 
chemotherapy. As a result, guidelines 
preferred to give all chemotherapy before 
surgery.  
Most of study population underwent 
mastectomy (65.5%), while those who 
received conservative treatment were (15.5%) 
and those of inoperable represented (19.1%). 
Two of the most influential publications that 
addressed breast conservation after 
neoadjuvant chemotherapy were from the two 
largest randomized trials (NSABP B-18 and 
EORTC) comparing neoadjuvant 
chemotherapy with adjuvant chemotherapy 
for patients with stage II or stage III breast 
cancer. The conclusion in both studies was 
that neoadjuvant chemotherapy offered an 
advantage because breast conservation rates 
were higher in the neoadjuvant chemotherapy 
groups22. However, it is important to 
recognize that approximately 60% of the 
patients enrolled in these studies were 
considered candidates for breast conservation 
at the time of diagnosis. This explains the low 
percentage of breast conservative treatment as 
most of patients included in the study were 
initially inoperable.   
The finding of this study, concerning response 
to neoadjuvant systemic chemotherapy, is 
similar to the data reported in the literature13,14. 
Clinical response rate is 80% while PCR is 
22%.   
Conclusion:  
In management of locally advanced breast 
cancer using neoadjuvant chemotherapy; this 
study showed results similar to literature and 
indicating that CAF regimen may remain 
equivalent to other new regimens as the first 
line of treatment.  Invasive ductal carcinoma 
is the predominant histological type of cancer 
and the most common grade is grade II and 
III.  
Pathological complete response is found to be 
better among those who received six cycles 
compared to those who received less cycles. 
Addition of more than six cycles didn’t seem 
to improve PCR and confirmation of this may 
need a prospective study with big number of 
patients.   
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